{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06299098",
            "orgStudyIdInfo": {
                "id": "R1033-OB-2288"
            },
            "organization": {
                "fullName": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss",
            "officialTitle": "A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity",
            "acronym": "COURAGE",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "a-study-to-test-if-trevogrumab-or-trevogrumab-with-garetosmab-when-taken-with-semaglutide-is-safe-and-how-well-they-work-in-adult-patients-with-obesity-for-weight-loss-and-fat-loss"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06-24",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06-24",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-01",
            "studyFirstSubmitQcDate": "2024-03-01",
            "studyFirstPostDateStruct": {
                "date": "2024-03-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is researching experimental drugs called trevogrumab and garetosmab (called \"study drugs\") in combination with another drug, semaglutide (Wegovy\u00ae). Part A of the study, the sponsor is only researching trevogrumab. Part B of the study the sponsor is researching trevogrumab, garetosmab, and Wegovy either alone or in different combinations with each other. Part A of the study is focused on healthy participants. Part B of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B of the study is to see how safe and effective the study drug is when combined with Wegovy.\n\nParts A and B of the study are looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug\n* How much study drug is in the blood at different times\n* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)",
            "detailedDescription": "Part A Healthy Volunteers\n\nPart B (starts after treatment for Part A has completed) Participants with Obesity"
        },
        "conditionsModule": {
            "conditions": [
                "Obesity"
            ],
            "keywords": [
                "Obesity without diabetes",
                "Quality of weight loss",
                "Fat mass loss",
                "Lean mass loss"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 624,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Part A Randomized 1:1",
                    "interventionNames": [
                        "Drug: Matching Placebo-Part A"
                    ]
                },
                {
                    "label": "Trevogrumab",
                    "type": "EXPERIMENTAL",
                    "description": "Part A Randomized 1:1",
                    "interventionNames": [
                        "Drug: Trevogrumab-Part A"
                    ]
                },
                {
                    "label": "Arm A0",
                    "type": "EXPERIMENTAL",
                    "description": "Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1",
                    "interventionNames": [
                        "Drug: Semaglutide",
                        "Drug: Matching Placebo-Trevogrumab",
                        "Drug: Matching Placebo-Garetosmab"
                    ]
                },
                {
                    "label": "Arm A1",
                    "type": "EXPERIMENTAL",
                    "description": "Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1",
                    "interventionNames": [
                        "Drug: Trevogrumab-Part B",
                        "Drug: Semaglutide",
                        "Drug: Matching Placebo-Trevogrumab",
                        "Drug: Matching Placebo-Garetosmab"
                    ]
                },
                {
                    "label": "Arm B0",
                    "type": "EXPERIMENTAL",
                    "description": "Part B Sema, low dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1",
                    "interventionNames": [
                        "Drug: Trevogrumab-Part B",
                        "Drug: Semaglutide",
                        "Drug: Matching Placebo-Trevogrumab",
                        "Drug: Matching Placebo-Garetosmab"
                    ]
                },
                {
                    "label": "Arm B1",
                    "type": "EXPERIMENTAL",
                    "description": "Part B Sema, low dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1",
                    "interventionNames": [
                        "Drug: Trevogrumab-Part B",
                        "Drug: Semaglutide",
                        "Drug: Matching Placebo-Garetosmab"
                    ]
                },
                {
                    "label": "Arm C0",
                    "type": "EXPERIMENTAL",
                    "description": "Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1",
                    "interventionNames": [
                        "Drug: Trevogrumab-Part B",
                        "Drug: Semaglutide",
                        "Drug: Matching Placebo-Trevogrumab",
                        "Drug: Matching Placebo-Garetosmab"
                    ]
                },
                {
                    "label": "Arm C1",
                    "type": "EXPERIMENTAL",
                    "description": "Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1",
                    "interventionNames": [
                        "Drug: Trevogrumab-Part B",
                        "Drug: Semaglutide",
                        "Drug: Matching Placebo-Garetosmab"
                    ]
                },
                {
                    "label": "Arm D0",
                    "type": "EXPERIMENTAL",
                    "description": "Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1",
                    "interventionNames": [
                        "Drug: Trevogrumab-Part B",
                        "Drug: Garetosmab",
                        "Drug: Semaglutide",
                        "Drug: Matching Placebo-Trevogrumab"
                    ]
                },
                {
                    "label": "Arm D1",
                    "type": "EXPERIMENTAL",
                    "description": "Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1",
                    "interventionNames": [
                        "Drug: Trevogrumab-Part B",
                        "Drug: Garetosmab",
                        "Drug: Semaglutide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Trevogrumab-Part A",
                    "description": "Administered IV or SC in Part A",
                    "armGroupLabels": [
                        "Trevogrumab"
                    ],
                    "otherNames": [
                        "REGN1033",
                        "GDF8"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Trevogrumab-Part B",
                    "description": "Administered SC in Part B",
                    "armGroupLabels": [
                        "Arm A1",
                        "Arm B0",
                        "Arm B1",
                        "Arm C0",
                        "Arm C1",
                        "Arm D0",
                        "Arm D1"
                    ],
                    "otherNames": [
                        "REGN1033",
                        "GDF8"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Garetosmab",
                    "description": "Administered IV in Part B",
                    "armGroupLabels": [
                        "Arm D0",
                        "Arm D1"
                    ],
                    "otherNames": [
                        "REGN2477",
                        "Activin A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Semaglutide",
                    "description": "Administered SC in Part B",
                    "armGroupLabels": [
                        "Arm A0",
                        "Arm A1",
                        "Arm B0",
                        "Arm B1",
                        "Arm C0",
                        "Arm C1",
                        "Arm D0",
                        "Arm D1"
                    ],
                    "otherNames": [
                        "Wegovy\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Matching Placebo-Part A",
                    "description": "Administered IV or SC in Part A",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Matching Placebo-Trevogrumab",
                    "description": "Administered SC in Part B",
                    "armGroupLabels": [
                        "Arm A0",
                        "Arm A1",
                        "Arm B0",
                        "Arm C0",
                        "Arm D0"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Matching Placebo-Garetosmab",
                    "description": "Administered IV in Part B",
                    "armGroupLabels": [
                        "Arm A0",
                        "Arm A1",
                        "Arm B0",
                        "Arm B1",
                        "Arm C0",
                        "Arm C1"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of treatment-emergent adverse events (TEAEs)",
                    "description": "Part A",
                    "timeFrame": "Baseline to week 7"
                },
                {
                    "measure": "Severity of TEAEs",
                    "description": "Part A",
                    "timeFrame": "Baseline to week 7"
                },
                {
                    "measure": "Percent body weight change",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Percent change in total fat mass",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Concentrations of trevogrumab in serum over time",
                    "description": "Part A and Part B",
                    "timeFrame": "Up to 75 weeks"
                },
                {
                    "measure": "Percent body weight change",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 52"
                },
                {
                    "measure": "Percent change in total fat mass",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 52"
                },
                {
                    "measure": "Percent change in total lean mass",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Change in waist circumference (cm)",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Percent change in body weight",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 52"
                },
                {
                    "measure": "Percent change in total lean mass",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 52"
                },
                {
                    "measure": "Percent change in regional measurements of body composition",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Percent change in gynoid fat mass",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Change in total lean mass:total fat mass ratio",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Proportion of weight loss attributable to fat mass loss",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Percent change in android (central) fat mass",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Percent change in thigh muscle volume (TMV)",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Body weight reduction of \u22655%",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Body weight reduction of \u226510%",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Body weight reduction of \u226515%",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Body weight reduction of \u226520%",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Body weight reduction of \u226525%",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Percent change in fasting serum triglycerides",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Percent change in total cholesterol",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Percent change in Apolipoprotein B (Apo B)",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Percent change in low-density lipoprotein cholesterol (LDL-C)",
                    "description": "Part B",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Change in physical function domain (5 items) score of Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQoLLite- CT)",
                    "description": "Part B IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patient's physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. This endpoint assesses the 'physical function score'. The scores range between 0-100 where higher scores indicate a better quality of life. A positive change score indicates an improvement since baseline.",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Change in physical functioning domain score of SF-36",
                    "description": "Part B Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.",
                    "timeFrame": "Baseline to week 26"
                },
                {
                    "measure": "Concentrations of garetosmab in serum over time",
                    "description": "Part B",
                    "timeFrame": "Up to 75 weeks"
                },
                {
                    "measure": "Incidence of anti-drug antibodies (ADA) to trevogrumab after repeated doses over time",
                    "description": "Part B",
                    "timeFrame": "Up to 75 weeks"
                },
                {
                    "measure": "Titer of ADAs to trevogrumab after repeated doses over time",
                    "description": "Part B",
                    "timeFrame": "Up to 75 weeks"
                },
                {
                    "measure": "Incidence of ADAs to garetosmab after repeated doses over time",
                    "description": "Part B",
                    "timeFrame": "Up to 75 weeks"
                },
                {
                    "measure": "Titer of ADAs to garetosmab after repeated doses over time",
                    "description": "Part B",
                    "timeFrame": "Up to 75 weeks"
                },
                {
                    "measure": "Incidence of TEAEs",
                    "description": "Part B",
                    "timeFrame": "Up to 75 weeks"
                },
                {
                    "measure": "Severity of TEAEs",
                    "description": "Part B",
                    "timeFrame": "Up to 75 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria\n\nPart A\n\n1. Male or female participants age \u226518 to \u226455 years of age at the time of screening\n2. BMI \u226518 and \u226432 kg/m2, at the screening visit\n\n   Part B\n3. Male or female participants \u226518 to \u226480 years of age at the time of screening\n4. BMI \u226530 kg/m2\n5. History of 1 or more self-reported unsuccessful dietary attempts to lose weight\n\nKey Exclusion Criteria\n\n1. History of diabetes (Type 2 or Type 1). History of gestational diabetes is permitted\n2. Previous bariatric surgery or planned bariatric surgery\n3. History of hypertrophic cardiomyopathy\n4. Abnormal electrocardiogram (ECG) findings at screening that meet Cornell voltage criteria for left ventricular hypertrophy\n5. Any malignancy in the past 5 years prior to screening (except for nonmelanoma skin cancer that has been resected with no evidence of metastatic disease for 3 years prior to screening)\n6. History of poorly controlled hypertension, as defined in the protocol\n7. Have a history of any other condition (such as known drug abuse, alcohol abuse, diagnosed eating disorder, or a severe mental illness) that, in the opinion of the investigator, may preclude the participant from following and completing the protocol\n8. Have history of use of marijuana/tetrahydrocannabinol (THC) within 3 months of enrollment and are unwilling to abstain from marijuana/THC use during the trial\n9. Has a history of any neuromuscular disorder (eg, multiple sclerosis, myasthenia gravis, myopathy, peripheral neuropathy, etc)\n\nNote: Other protocol-defined Inclusion/ Exclusion Criteria apply",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials Administrator",
                    "role": "CONTACT",
                    "phone": "844-734-6643",
                    "email": "clinicaltrials@regeneron.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trial Management",
                    "affiliation": "Regeneron Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Pinnacle Research Group",
                    "status": "RECRUITING",
                    "city": "Anniston",
                    "state": "Alabama",
                    "zip": "36207",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.65983,
                        "lon": -85.83163
                    }
                },
                {
                    "facility": "Cullman Clinical Trials",
                    "status": "RECRUITING",
                    "city": "Cullman",
                    "state": "Alabama",
                    "zip": "35055",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.17482,
                        "lon": -86.84361
                    }
                },
                {
                    "facility": "Foothills Research Center/ CCT Research",
                    "status": "RECRUITING",
                    "city": "Phoenix",
                    "state": "Arizona",
                    "zip": "85044",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.44838,
                        "lon": -112.07404
                    }
                },
                {
                    "facility": "Anaheim Clinical Trials",
                    "status": "RECRUITING",
                    "city": "Anaheim",
                    "state": "California",
                    "zip": "92801",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.83529,
                        "lon": -117.9145
                    }
                },
                {
                    "facility": "ProSciento",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Chula Vista",
                    "state": "California",
                    "zip": "91911",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.64005,
                        "lon": -117.0842
                    }
                },
                {
                    "facility": "Velocity Clinical Research",
                    "status": "RECRUITING",
                    "city": "La Mesa",
                    "state": "California",
                    "zip": "91941",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.76783,
                        "lon": -117.02308
                    }
                },
                {
                    "facility": "Valiance Clinical Research",
                    "status": "RECRUITING",
                    "city": "S. Gate",
                    "state": "California",
                    "zip": "90280",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.95474,
                        "lon": -118.21202
                    }
                },
                {
                    "facility": "Valiance Clinical Research",
                    "status": "RECRUITING",
                    "city": "Tarzana",
                    "state": "California",
                    "zip": "91356",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.17334,
                        "lon": -118.55397
                    }
                },
                {
                    "facility": "Jacksonville Center for Clinical Research",
                    "status": "RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32216",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "Precision Clinical Research, LLC",
                    "status": "RECRUITING",
                    "city": "Sunrise",
                    "state": "Florida",
                    "zip": "33351",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.13397,
                        "lon": -80.1131
                    }
                },
                {
                    "facility": "North Georgia Clinical Research",
                    "status": "RECRUITING",
                    "city": "Woodstock",
                    "state": "Georgia",
                    "zip": "30189",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.10149,
                        "lon": -84.51938
                    }
                },
                {
                    "facility": "East-West Medical Research Institute",
                    "status": "RECRUITING",
                    "city": "Honolulu",
                    "state": "Hawaii",
                    "zip": "96814",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 21.30694,
                        "lon": -157.85833
                    }
                },
                {
                    "facility": "Elite Clinical Trials",
                    "status": "RECRUITING",
                    "city": "Blackfoot",
                    "state": "Idaho",
                    "zip": "83221",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.19047,
                        "lon": -112.34498
                    }
                },
                {
                    "facility": "The South Bend Clinic Center for Research",
                    "status": "RECRUITING",
                    "city": "South Bend",
                    "state": "Indiana",
                    "zip": "46617",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.68338,
                        "lon": -86.25001
                    }
                },
                {
                    "facility": "Cotton O'Neil Clinical Research Center",
                    "status": "RECRUITING",
                    "city": "Topeka",
                    "state": "Kansas",
                    "zip": "66606",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.04833,
                        "lon": -95.67804
                    }
                },
                {
                    "facility": "L-MARC Research Center",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40213",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "Tandem Clinical Research",
                    "status": "RECRUITING",
                    "city": "Marrero",
                    "state": "Louisiana",
                    "zip": "70072",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.89937,
                        "lon": -90.10035
                    }
                },
                {
                    "facility": "Clinvest Research",
                    "status": "RECRUITING",
                    "city": "Springfield",
                    "state": "Missouri",
                    "zip": "65807",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.21533,
                        "lon": -93.29824
                    }
                },
                {
                    "facility": "Mercury Street Medical Group, PLLC",
                    "status": "RECRUITING",
                    "city": "Butte",
                    "state": "Montana",
                    "zip": "59701",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 46.00382,
                        "lon": -112.53474
                    }
                },
                {
                    "facility": "Accellacare",
                    "status": "RECRUITING",
                    "city": "Raleigh",
                    "state": "North Carolina",
                    "zip": "27609",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.7721,
                        "lon": -78.63861
                    }
                },
                {
                    "facility": "Accellacare of Salisbury",
                    "status": "RECRUITING",
                    "city": "Salisbury",
                    "state": "North Carolina",
                    "zip": "284144",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.67097,
                        "lon": -80.47423
                    }
                },
                {
                    "facility": "Accellacare of Piedmont",
                    "status": "RECRUITING",
                    "city": "Statesville",
                    "state": "North Carolina",
                    "zip": "28625",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.78264,
                        "lon": -80.8873
                    }
                },
                {
                    "facility": "Accellacare of Wilmington",
                    "status": "RECRUITING",
                    "city": "Wilmington",
                    "state": "North Carolina",
                    "zip": "28401",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.22573,
                        "lon": -77.94471
                    }
                },
                {
                    "facility": "Tribe Clinical Research, LLC.",
                    "status": "RECRUITING",
                    "city": "Greenville",
                    "state": "South Carolina",
                    "zip": "29607",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.85262,
                        "lon": -82.39401
                    }
                },
                {
                    "facility": "Chattanooga Medical Research",
                    "status": "RECRUITING",
                    "city": "Chattanooga",
                    "state": "Tennessee",
                    "zip": "37412",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.04563,
                        "lon": -85.30968
                    }
                },
                {
                    "facility": "Consano Clinical Research",
                    "status": "RECRUITING",
                    "city": "Shavano Park",
                    "state": "Texas",
                    "zip": "78231",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.58495,
                        "lon": -98.55252
                    }
                },
                {
                    "facility": "Health Research of Hampton Roads, Inc.",
                    "status": "RECRUITING",
                    "city": "Newport News",
                    "state": "Virginia",
                    "zip": "23606",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.08339,
                        "lon": -76.46965
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",
            "accessCriteria": "Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf",
            "url": "https://vivli.org/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009765",
                    "term": "Obesity"
                }
            ],
            "ancestors": [
                {
                    "id": "D000050177",
                    "term": "Overweight"
                },
                {
                    "id": "D000044343",
                    "term": "Overnutrition"
                },
                {
                    "id": "D000009748",
                    "term": "Nutrition Disorders"
                },
                {
                    "id": "D000001835",
                    "term": "Body Weight"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5114",
                    "name": "Body Weight",
                    "relevance": "LOW"
                },
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "asFound": "Obesity",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "relevance": "LOW"
                },
                {
                    "id": "M18102",
                    "name": "Weight Loss",
                    "relevance": "LOW"
                },
                {
                    "id": "M26186",
                    "name": "Overweight",
                    "relevance": "LOW"
                },
                {
                    "id": "M25307",
                    "name": "Overnutrition",
                    "relevance": "LOW"
                },
                {
                    "id": "M12684",
                    "name": "Nutrition Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000591245",
                    "term": "Semaglutide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000097789",
                    "term": "Glucagon-Like Peptide-1 Receptor Agonists"
                },
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M353561",
                    "name": "Semaglutide",
                    "asFound": "Stretching",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9043",
                    "name": "Glucagon",
                    "relevance": "LOW"
                },
                {
                    "id": "M26997",
                    "name": "Glucagon-Like Peptide 1",
                    "relevance": "LOW"
                },
                {
                    "id": "M3401",
                    "name": "Glucagon-Like Peptide-1 Receptor Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                }
            ]
        }
    },
    "hasResults": false
}